TR201722186A2 - Pharmaceutical compositions of dabigatran - Google Patents

Pharmaceutical compositions of dabigatran Download PDF

Info

Publication number
TR201722186A2
TR201722186A2 TR2017/22186A TR201722186A TR201722186A2 TR 201722186 A2 TR201722186 A2 TR 201722186A2 TR 2017/22186 A TR2017/22186 A TR 2017/22186A TR 201722186 A TR201722186 A TR 201722186A TR 201722186 A2 TR201722186 A2 TR 201722186A2
Authority
TR
Turkey
Prior art keywords
pharmaceutical compositions
dabigatran
dabigatran etexilate
core
pharmaceutically acceptable
Prior art date
Application number
TR2017/22186A
Other languages
Turkish (tr)
Inventor
Palantöken Arzu
Türkyilmaz Ali̇
Gülkok Yildiz
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2017/22186A priority Critical patent/TR201722186A2/en
Priority to EP18847286.4A priority patent/EP3731830A1/en
Priority to PCT/TR2018/050900 priority patent/WO2019132838A1/en
Publication of TR201722186A2 publication Critical patent/TR201722186A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to pharmaceutical compositions for oral administration comprising a core comprising dabigatran etexilate free base or a pharmaceutically acceptable salt of dabigatran etexilate and a separating layer and an acid layer.
TR2017/22186A 2017-12-27 2017-12-27 Pharmaceutical compositions of dabigatran TR201722186A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2017/22186A TR201722186A2 (en) 2017-12-27 2017-12-27 Pharmaceutical compositions of dabigatran
EP18847286.4A EP3731830A1 (en) 2017-12-27 2018-12-26 Pharmaceutical compositions of dabigatran
PCT/TR2018/050900 WO2019132838A1 (en) 2017-12-27 2018-12-26 Pharmaceutical compositions of dabigatran

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/22186A TR201722186A2 (en) 2017-12-27 2017-12-27 Pharmaceutical compositions of dabigatran

Publications (1)

Publication Number Publication Date
TR201722186A2 true TR201722186A2 (en) 2019-07-22

Family

ID=65444314

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/22186A TR201722186A2 (en) 2017-12-27 2017-12-27 Pharmaceutical compositions of dabigatran

Country Status (3)

Country Link
EP (1) EP3731830A1 (en)
TR (1) TR201722186A2 (en)
WO (1) WO2019132838A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111921003B (en) * 2020-09-04 2022-06-03 东南大学 A kind of magnetic response hyperthermia controllable degradable embolization microsphere and its preparation method and application

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (en) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN
CA2476054C (en) 2002-03-07 2011-11-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for the oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino)-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino)-propionic acid ethyl ester and the salts thereof
DE10337697A1 (en) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablet containing 3 - [(2 - {[4- (hexyloxycarbonylamino-iminomethyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionic acid ethyl ester or its salts
DE102005020002A1 (en) 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologically acceptable salts of 3 - [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionate
PL2588090T3 (en) 2010-07-01 2017-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
US9006448B2 (en) 2010-12-06 2015-04-14 Msn Laboratories Private Limited Process for the preparation of benzimidazole derivatives and its salts
CN103127109B (en) * 2013-02-05 2014-08-13 南京华威医药科技开发有限公司 Pharmaceutical composition containing dabigatran etexilate or salt and hydrate thereof
US10675276B2 (en) * 2014-11-03 2020-06-09 Hangzhou Solipharma Co., Ltd. Dosing preparation of dabigatran etexilate or a salt thereof and a preparation method thereof

Also Published As

Publication number Publication date
WO2019132838A1 (en) 2019-07-04
EP3731830A1 (en) 2020-11-04

Similar Documents

Publication Publication Date Title
JOP20200122A1 (en) Compounds useful for inhibiting cdk7
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
CL2017003320A1 (en) Pharmaceutical formulations containing tenofovir and emtricitabine
EA201201263A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DAGIGATRAN ETEXYLATE
IN2014MN02245A (en)
EA201992116A1 (en) PHARMACEUTICAL COMPOSITIONS OF FLOROGLUCINOL AND TRIMETHYLFLOROGLUCINOL
IL271108A (en) Solid preparation of cariprazine for oral administration
CY1115556T1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT INCLUDES DAVIGATRAN
IN2013CH05441A (en)
EA202092829A1 (en) CONTROLLED RELEASE TOPACITINIB COMPOSITIONS
IL264880A (en) Formulations for oral administration of active agents
MX387731B (en) ORAL PHARMACEUTICAL COMPOSITIONS OF MESALAZINE.
IN2014MU01042A (en)
MY204588A (en) Delayed release deferiprone tablets and methods of using the same
MX385518B (en) FORMULATION HAVING ENHANCED pH-DEPENDENT DRUG RELEASE CHARACTERISTICS, CONTAINING ESOMEPRAZOLE OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS.
WO2016168553A8 (en) Deuterated obeticholic acid
MX364946B (en) Improved adjuvant system for oral vaccine adminstration.
TN2018000214A1 (en) Alkyl dihydroquinoline sulfonamide compounds
WO2016142821A3 (en) Compositions containing a thrombin inhibitor
MY182008A (en) Pharmaceutical formulations
IN2014MN02485A (en)
MX2023012198A (en) Amantadine compositions, preparations thereof, and methods of use.
EA201991286A1 (en) A SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING TENOFOVIR AND EMTRITSITABIN
TR201722186A2 (en) Pharmaceutical compositions of dabigatran
WO2019004980A3 (en) Solid oral pharmaceutical compositions of dabigatran etexilate